

SECURITIES AND EXCHANGE COMMISSION

FORM N-MFP

Monthly schedule of portfolio holdings of money market funds

Filing Date: **2011-11-07** | Period of Report: **2011-10-31**
SEC Accession No. **0000357057-11-00080**

([HTML Version](#) on [secdatabase.com](#))

FILER

FIDELITY MASSACHUSETTS MUNICIPAL TRUST

CIK: **357057** | IRS No.: **042760270** | State of Incorpor.: **MA** | Fiscal Year End: **0131**
Type: **N-MFP** | Act: **33** | File No.: **811-03361** | Film No.: **111183111**

Mailing Address
*P.O. BOX 650471
MAILZONE DW4B
DALLAS TX 75265-0471*

Business Address
*82 DEVONSHIRE ST
BOSTON MA 02109
6174391648*

UNITED STATES SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

FORM N-MFP

OMB APPROVAL

OMB Number: 3235-0657
Expires: 05/31/2013
Estimated average burden
hours per response 10.9

MONTHLY SCHEDULE OF PORTFOLIO HOLDINGS OF
MONEY MARKET FUNDS

1. Identity Information

Is this an electronic copy of an official filing submitted in paper format? No

Report date: October 31, 2011

CIK Number of Registrant: 0000357057

EDGAR Series Identifier: S000007115

Total number of share classes in the series: 1

Do you anticipate this will be the fund's final filing on Form N-MFP? No

If this is not a final filing, has the fund acquired or merged with another fund since the last filing? No

Part 1: Information about the Fund

A. Series-Level Information

Item 1. Securities Act File Number: 002-75537

Item 2. Investment Adviser

Investment Adviser

FIDELITY MANAGEMENT & RESEARCH COMPANY (FMR)

SEC file number of investment adviser

801-07884

Item 3. Sub-Adviser. If a fund has one or more sub-advisers, disclose the name of each sub-adviser

Sub Adviser	SEC File Number
FIDELITY INVESTMENTS MONEY MANAGEMENT, INC.	801-34590
FIDELITY MANAGEMENT & RESEARCH (U.K.), INC.	801-28773
FIDELITY MANAGEMENT & RESEARCH (HONG KONG) LIMITED	801-69507
FIDELITY MANAGEMENT & RESEARCH (JAPAN) INC	801-69571

Item 4. Independent Public Accountant

Name

City, State

DELOITTE & TOUCHE LLP

Boston, MA

Item 5. Administrator. If a fund has one or more administrators, disclose the name of each administrator

Administrator

None

Item 6. Transfer Agent

Transfer Agent

CITIBANK, N.A.

CIK number

0000840464

SEC file number of transfer agent

085-10232

FIDELITY INVESTMENTS INSTIT. OPERATIONS CO.

0000862124

084-01839

Item 7. Master-Feeder Funds. Is this a feeder fund? No

Item 8. Master-Feeder Funds. Is this a master fund? No

Item 9. Is this series primarily used to fund insurance company separate accounts? No

Item 10. Category. Indicate the category that most closely identifies the money market fund: Single State Fund

Item 11. Dollar weighted average portfolio maturity: 21 days

Item 12. Dollar weighted average life maturity. Calculate the dollar weighted average portfolio maturity without reference to the exceptions in rule 2a-7(d) regarding interest rate readjustments: 22 days

Item 13. Total value of portfolio securities at amortized cost, to the nearest cent: [\\$5,047,987,281.13](#)

Item 14. Total value of other assets, to the nearest cent: [\\$111,000,565.09](#)

Item 15. Total value of liabilities, to the nearest cent: [\\$4,520,938.47](#)

Item 16. Net assets of the series, to the nearest cent: [\\$5,154,466,907.75](#)

Item 17. 7-day gross yield: [0.15%](#)

Item 18. Shadow Price of the Series. Net asset value per share most recent calculated using available market quotations (or an appropriate substitute that reflects current market conditions), to the nearest hundredth of a cent:

	Net Asset Value per Share	Date Calculated
Including capital support agreement	\$1.0009	2011-10-31
Excluding capital support agreement	\$1.0009	2011-10-31

B. Class-Level Information.

Item 19. EDGAR Class Identifier: [C000019444](#)

Item 20. Minimum Initial Investment: [\\$5,000.00](#)

Item 21. Item 21. Net assets of the Class, to the nearest cent: [\\$5,154,466,907.75](#)

Item 22. Item 22. Net asset value per share for purposes of distributions, redemptions, and repurchase, to the nearest cent: [\\$1.00](#)

Item 23. Net shareholder flow activity for the month ended: [\\$31,791,522.92](#)

Gross subscriptions for the month ended(including dividend reinvestments):	\$949,024,915.50
Gross redemptions for the month ended:	\$917,233,392.58

Item 24. 7-day net yield: [0.01%](#)

Item 25. Shadow Price of Each Class. Net asset value per share most recent calculated using available market quotations (or an appropriate substitute that reflects current market conditions)

	Net Asset Value per Share	Date Calculated
Including the value of any capital support agreement:	\$1.0009	2011-10-31
Excluding the value of any capital support agreement:	\$1.0009	2011-10-31

Part 2 - Schedule of Portfolio Securities

Security

Item 26. The name of the issuer: [Boston Indl. Dev. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Boston Indl. Dev. Rev., 0.22% \(New Boston Seafood Ctr., Inc. Proj.\) Series 1997, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [100883AH0](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,740,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,740,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.05%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,740,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,740,000.00](#)

Security

Item 26. The name of the issuer: [Boston Wtr. & Swr. Commission Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Boston Wtr. & Swr. Commission Rev., 0.08% Series 1994 A, LOC State Street Bank & Trust Co., Boston VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [101029HM1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
STATE ST BK & TR CO BOSTON	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$13,200,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$13,200,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.26%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$13,200,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$13,200,000.00**

Security

Item 26. The name of the issuer: **Canton Hsg. Auth. Multi-family Hsg. Mtg. Rev.**

Item 27. The title of the issue (including coupon or yield): **Canton Hsg. Auth. Multi-family Hsg. Mtg. Rev., 0.14% (Canton Arboretum Apt. Proj.) Series 1999, LOC Fannie Mae Mtg. pass-thru certificates VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **138270AB9**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
FANNIE MAE	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
FANNIE MAE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$7,665,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$7,665,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.15%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$7,665,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$7,665,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Bay Trans. Auth. Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Bay Trans. Auth. Sales Tax Rev., 0.11% Series 2008 A2, \(Liquidity Facility JPMorgan Chase Bank\) VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575579TK3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$48,150,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$48,150,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.93%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$48,150,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$48,150,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Bay Trans. Auth. Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Bay Trans. Auth. Sales Tax Rev., 0.12% Series 2008 A1, \(Liquidity Facility JPMorgan Chase Bank\) VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575579TJ6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$89,500,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$89,500,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.74%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$89,500,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$89,500,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Bay Trans. Auth. Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Bay Trans. Auth. Sales Tax Rev., 0.14% Participating VRDN Series PT 4368, \(Liquidity Facility Wells Fargo & Co.\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [74703TTB7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
WELLS FARGO & CO NEW	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$4,985,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$4,985,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.10%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$4,985,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$4,985,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Bay Trans. Auth. Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Bay Trans. Auth. Sales Tax Rev., 0.17% Participating VRDN Series Clipper 07 18, \(Liquidity Facility State Street Bank & Trust Co., Bosto](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [18886PUV5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
STATE ST BK & TR CO BOSTON	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$100,175,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$100,175,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.94%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$100,175,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$100,175,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dept. of Trans. Metropolitan Hwy. Sys. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dept. of Trans. Metropolitan Hwy. Sys. Rev., 0.10% Series 2010 A2, LOC Wells Fargo Bank NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57563CBG6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
WELLS FARGO BK NATL ASSN	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
WELLS FARGO BK NATL ASSN	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$95,065,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$95,065,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.84%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$95,065,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$95,065,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dept. of Trans. Metropolitan Hwy. Sys. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dept. of Trans. Metropolitan Hwy. Sys. Rev., 0.12% Series 2010 A1, LOC Citibank NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57563CBF8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
CITIBANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$35,675,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$35,675,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.69%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$35,675,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$35,675,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dept. of Trans. Metropolitan Hwy. Sys. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dept. of Trans. Metropolitan Hwy. Sys. Rev., 0.15% Series 2010 A6, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57563CAF9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$63,990,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$63,990,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.24%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$63,990,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$63,990,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dept. of Trans. Metropolitan Hwy. Sys. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dept. of Trans. Metropolitan Hwy. Sys. Rev., 0.15% Series 2010 A3, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57563CAC6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$50,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$50,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.97%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$50,000,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$50,000,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Incl. Dev. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Incl. Dev. Rev., 0.55% \(Monkiewicz Realty Trust Proj.\) LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583EAP9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
-----------------------	--	--

BANK OF AMERICA NA

N/A

N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$3,240,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$3,240,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.06%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$3,240,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$3,240,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Incl. Dev. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Incl. Dev. Rev., 0.60% \(Charm Sciences, Inc. Proj.\) Series 1999 A, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583EAJ3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.04%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,000,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,000,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Multi-family Hsg. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Multi-family Hsg. Rev., 0.14% \(Salem Heights Apts. Proj.\) Series 2003 A, LOC Fed. Home Ln. Bank of Boston VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583XAE2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
FEDERAL HOME LN BK OF BOSTON	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
FEDERAL HOME LN BK OF BOSTON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$15,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$15,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.29%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$15,000,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$15,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Multi-family Hsg. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Multi-family Hsg. Rev., 0.14% \(Tammy Brook Apts. Proj.\) Series 2009, LOC Freddie Mac VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583XBN1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
FREDDIE MAC	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
FREDDIE MAC	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$6,500,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$6,500,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.13%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$6,500,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$6,500,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Multi-family Hsg. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Multi-family Hsg. Rev., 0.15% \(Georgetown Village Apts. Proj.\) Series 2003 A, LOC Fannie Mae Mtg. pass-thru certificates](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583XAC6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
FANNIE MAE	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
FANNIE MAE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$18,650,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$18,650,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.36%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$18,650,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$18,650,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Multi-family Hsg. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Multi-family Hsg. Rev., 0.17% \(Archstone Reading Apts. Proj.\) Series 2004 A, LOC Freddie Mac VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583XAQ5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
FREDDIE MAC	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
FREDDIE MAC	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$24,840,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$24,840,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.48%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$24,840,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$24,840,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Multi-family Hsg. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Multi-family Hsg. Rev., 0.17% \(Casco Crossing Proj.\) LOC Fannie Mae Mtg. pass-thru certificates VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583XAR3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
FANNIE MAE	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
-----------	--	--------------------------------

FANNIE MAE N/A

N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$10,535,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$10,535,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.20%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$10,535,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$10,535,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Dev. Fin. Agcy. Multi-family Hsg. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Dev. Fin. Agcy. Multi-family Hsg. Rev., 0.17% (Avalon Acton Apts. Proj.) Series 2006, LOC Fannie Mae Mtg. pass-thru certificates VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57583XBG6**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
FANNIE MAE	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
FANNIE MAE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$38,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$38,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.74%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$38,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$38,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.06% \(Boston Univ. Proj.\) Series U-5B, LOC Fed. Home Ln. Bank of Boston VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RP58](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
FEDERAL HOME LN BK OF BOSTON	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
FEDERAL HOME LN BK OF BOSTON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$38,805,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$38,805,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.75%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$38,805,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$38,805,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.07% \(Boston Univ. Proj.\) Series U6E, LOC Bank of Nova Scotia New York Branch VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RWD3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF NOVA SCOTIA NY BRH	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF NOVA SCOTIA NY BRH	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$23,325,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$23,325,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.45%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$23,325,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$23,325,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.08% \(Babson College Proj.\) Series 2008 A, LOC Fed. Home Ln. Bank of Boston VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RL86](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
FEDERAL HOME LN BK OF BOSTON	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
FEDERAL HOME LN BK OF BOSTON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$22,530,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$22,530,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.44%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$22,530,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$22,530,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.08% \(Masonic Nursing Home Proj.\) Series 2002 B, LOC TD Banknorth, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RP82](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
TD BANK NA WILMINGTON DE	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$17,705,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$17,705,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.34%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$17,705,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$17,705,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.08% \(Boston Univ. Proj.\) Series U5A, LOC Fed. Home Ln. Bank of Boston VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RP41](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
-----------------------	--	--

FEDERAL HOME LN BK
OF BOSTON

N/A

N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
FEDERAL HOME LN BK OF BOSTON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$32,325,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$32,325,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.63%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$32,325,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$32,325,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.09% \(ISO New England, Inc. Proj.\) Series 2005, LOC TD Banknorth, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RAA3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
TD BANK NA WILMINGTON DE	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$10,505,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$10,505,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.20%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$10,505,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$10,505,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Dev. Fin. Agcy. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Dev. Fin. Agcy. Rev., 0.10% (Worcester Polytechnic Institute Proj.) Series 2008 A, LOC TD Banknorth, NA VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57583RTX3**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
TD BANK NA WILMINGTON DE	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$18,740,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$18,740,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.36%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$18,740,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$18,740,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.10% \(Berkshire School Proj.\) Series 2001, LOC JPMorgan Chase Bank VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583R2T1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$10,045,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$10,045,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.19%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$10,045,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$10,045,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.11% \(Edgewood Retirement Cmnty. Proj.\) Series 2000 A, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RB79](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,020,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$1,020,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.02%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$1,020,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$1,020,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.11% \(Clark Univ. Proj.\) LOC TD Banknorth, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RUU7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
TD BANK NA WILMINGTON DE	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$33,295,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$33,295,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.65%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$33,295,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$33,295,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Dev. Fin. Agcy. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Dev. Fin. Agcy. Rev., 0.13% (Boston Univ. Proj.) Series U6C, LOC JPMorgan Chase Bank VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57583RWB7**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-01**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,600,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$1,600,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.03%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$1,600,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$1,600,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.13% \(Olin College Proj.\) Series 2008 C2, LOC RBS Citizens NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RZF5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Second Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
RBS CITIZENS NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$7,500,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$7,500,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.15%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$7,500,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$7,500,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Dev. Fin. Agcy. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Dev. Fin. Agcy. Rev., 0.13% (Olin College Proj.) Series 2008 C3, LOC RBS Citizens NA VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57583RZG3**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **Second Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-01**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-01**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
RBS CITIZENS NA	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
RBS CITIZENS NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$42,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$42,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.81%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$42,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$42,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.13% \(YMCA of Greater Boston Proj.\) Series 2004 A, LOC Fed. Home Ln. Bank of Boston VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583F5X5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
FEDERAL HOME LN BK OF BOSTON	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
FEDERAL HOME LN BK OF BOSTON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$17,165,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$17,165,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.33%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$17,165,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$17,165,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.13% Participating VRDN Series ROC II R 11896, \(Liquidity Facility Citibank NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583R7H2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$19,800,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$19,800,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.38%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$19,800,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$19,800,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.13% \(Wilber School Apts. Proj.\) Series 2008 A, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RD77](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$7,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$7,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.14%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$7,000,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$7,000,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.13% \(Abby Kelley Foster Charter Pub. School Proj.\) Series 2008, LOC TD Banknorth, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RWJ0](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
-----------------------	--	--

TD BANK NA WILMINGTON DE	N/A	N/A
-----------------------------	-----	-----

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$4,575,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$4,575,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.09%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$4,575,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$4,575,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.14% Participating VRDN Series WF 10 56C, \(Liquidity Facility Wells Fargo Bank NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [94985NZX2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
WELLS FARGO BK NATL ASSN	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$19,915,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$19,915,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.39%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$19,915,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$19,915,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.14% \(Saint Mark's School Proj.\) Series 2004, LOC JPMorgan Chase Bank VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583F4Z1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$5,085,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$5,085,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.10%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$5,085,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$5,085,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.14% \(Smith College Proj.\) Series 2007, \(Liquidity Facility Bank of America NA\) VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583R2R5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	SMITH COLLEGE, MA	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$46,560,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$46,560,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.90%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$46,560,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$46,560,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.14% Participating VRDN Series Putters 3840, \(Liquidity Facility JPMorgan Chase Bank\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [46633VG45](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$5,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$5,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.10%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$5,000,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$5,000,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.14% \(Fay School Proj.\) Series 2008, LOC TD Banknorth, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RTZ8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
TD BANK NA WILMINGTON DE	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$5,950,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$5,950,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.12%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$5,950,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$5,950,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.14% \(Seven Hills Foundation and Affiliates Proj.\) Series 2008 B, LOC TD Banknorth, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RZW8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
-----------------------	--	--

TD BANK NA WILMINGTON DE	N/A	N/A
-----------------------------	-----	-----

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$5,265,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$5,265,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.10%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$5,265,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$5,265,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.14% \(Briarwood Retirement Cmnty. Proj.\) Series 2004 A, LOC Manufacturers & Traders Trust Co. VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583F5P2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
MANUFACTURERS & TRADERS TR CO	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
MANUFACTURERS & TRADERS TR CO	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$6,825,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$6,825,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.13%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$6,825,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$6,825,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Dev. Fin. Agcy. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Dev. Fin. Agcy. Rev., 0.14% Participating VRDN Series Putters 3873, (Liquidity Facility JPMorgan Chase Bank)**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **46633VR35**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$2,500,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$2,500,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.05%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$2,500,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$2,500,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.15% Participating VRDN Series Putters 3867, \(Liquidity Facility JPMorgan Chase & Co.\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [46633VP86](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE & CO	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$20,870,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$20,870,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.40%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$20,870,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$20,870,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.15% Series 2007 B, LOC JPMorgan Chase Bank VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RTM7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$13,335,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$13,335,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.26%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$13,335,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$13,335,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.15% \(Fessenden School Proj.\) Series 2001, LOC JPMorgan Chase Bank VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583FXX4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$11,770,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$11,770,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.23%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$11,770,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$11,770,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.18% \(Fifteen-O-Five West Housatonic LLC Proj.\) Series 2007, LOC HSBC Bank USA, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RKW4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
HSBC BANK USA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
-----------	--	--------------------------------

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$2,655,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$2,655,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.05%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$2,655,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$2,655,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Dev. Fin. Agcy. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Dev. Fin. Agcy. Rev., 0.22% (Institute of Contemporary Art Proj.) Series 2004 A, LOC Bank of America NA VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57583F4X6**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$3,750,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$3,750,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.07%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$3,750,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$3,750,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.22% \(Ed. Lawrence Academy Proj.\) Series 2003 A, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583FN23](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$1,655,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$1,655,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.03%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$1,655,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$1,655,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.24% \(Williston Northampton School Proj.\) Series 2010, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RZ40](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$6,060,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$6,060,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.12%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$6,060,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$6,060,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.25% \(Judge Rotenburg Ctr. Proj.\) Series 2003, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583FQ87](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$8,645,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$8,645,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.17%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$8,645,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$8,645,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.25% \(Justice Resource Institute Proj.\) Series 2008, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583RD85](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$11,905,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$11,905,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.23%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$11,905,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$11,905,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Solid Waste Disp. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Solid Waste Disp. Rev., 0.13% \(Wheelabrator Millbury Proj.\) LOC JPMorgan Chase Bank VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583HAF4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$10,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$10,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.19%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$10,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$10,000,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Gen. Oblig.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Gen. Oblig., 0.09% Series 2001 C, (Liquidity Facility State Street Bank & Trust Co., Boston) VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **575827X54**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
STATE ST BK & TR CO BOSTON	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$187,275,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$187,275,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **3.63%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$187,275,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$187,275,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 0.10% \(Central Artery Proj.\) Series 2000 B, \(Liquidity Facility State Street Bank & Trust Co., Boston\) VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575827R51](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
STATE ST BK & TR CO BOSTON	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$18,880,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$18,880,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.37%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$18,880,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$18,880,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 0.10% Series 1998 A, \(Liquidity Facility JPMorgan Chase Bank\) VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575827SF8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$85,595,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$85,595,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.66%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$85,595,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$85,595,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 0.14% Participating VRDN Series Putters 2648, \(Liquidity Facility JPMorgan Chase Bank\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57582PHZ6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$5,550,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$5,550,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.11%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$5,550,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$5,550,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 0.14% Participating VRDN Series Putters 3896, \(Liquidity Facility JPMorgan Chase Bank\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [46633VU98](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$3,755,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$3,755,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.07%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$3,755,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$3,755,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Gen. Oblig.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Gen. Oblig., 0.14% Participating VRDN Series EGL 07 0124, (Liquidity Facility Citibank NA)**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57582PGR5**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$12,235,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$12,235,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.24%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$12,235,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$12,235,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Gen. Oblig.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Gen. Oblig., 0.14% Participating VRDN Series EGL 07 0149, (Liquidity Facility Citibank NA)**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57582PGZ7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$29,300,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$29,300,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.57%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$29,300,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$29,300,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 0.14% Participating VRDN Series Putters 2022, \(Liquidity Facility JPMorgan Chase Bank\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57582PGC8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$22,040,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$22,040,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.43%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$22,040,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$22,040,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 0.15% Participating VRDN Series Putters 3699, \(Liquidity Facility JPMorgan Chase Bank\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [46633VSJ9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$3,920,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$3,920,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.08%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$3,920,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$3,920,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Gen. Oblig.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Gen. Oblig., 0.17% Participating VRDN Series Clipper 07 06, (Liquidity Facility State Street Bank & Trust Co., Boston)**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **18886PRV9**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
STATE ST BK & TR CO BOSTON	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$53,850,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$53,850,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.04%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$53,850,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$53,850,000.00**

Security

- Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)
- Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 0.17% Participating VRDN Series Clipper 07 39, \(Liquidity Facility State Street Bank & Trust Co., Boston\)](#)
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [18886PA39](#)
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)
- Brief description: (optional): [Not Provided]
- Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
- Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
- Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

- Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)
- Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)
- Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
STATE ST BK & TR CO BOSTON	N/A	N/A

- Item 38. Does the security have a Guarantee? [No](#)
- Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
- Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$13,325,000.00](#)
- Item 41. The total current amortized cost, to the nearest cent: [\\$13,325,000.00](#)
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.26%](#)
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$13,325,000.00](#)
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$13,325,000.00](#)

Security

- Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)
- Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 0.20% Participating VRDN Series MT 725, \(Liquidity Facility Bank of America NA\)](#)
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [74703YW89](#)
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)
- Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$10,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$10,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.19%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$10,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$10,000,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Health & Edl. Facilities Auth. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Health & Edl. Facilities Auth. Rev., 0.05% (Massachusetts Institute of Technology Proj.) Series 2001 J1 VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57585KSW9**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
MASSACHUSETTS INST TECH, MA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$10,500,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$10,500,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.20%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$10,500,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$10,500,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Health & Edl. Facilities Auth. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Health & Edl. Facilities Auth. Rev., 0.05% (Wellesley College Proj.) Series B VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **575851NQ9**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
WELLESLEY COLLEGE, MA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$4,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$4,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.08%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$4,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$4,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.05% \(Harvard Univ. Proj.\) Series Y VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57585KKV9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
PRESIDENT & FELLOWS HARVARD CO	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$19,025,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$19,025,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.37%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$19,025,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$19,025,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.06% \(Children's Hosp. Proj.\) Series 2010 N1, LOC TD Banknorth, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586EUH2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
TD BANK NA WILMINGTON DE	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$12,025,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$12,025,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.23%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$12,025,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$12,025,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.06% \(Partners HealthCare Sys., Inc. Proj.\) Series 2005 F, LOC TD Banknorth, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CGB5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
TD BANK NA WILMINGTON DE	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$10,160,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$10,160,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.20%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$10,160,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$10,160,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Health & Edl. Facilities Auth. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Health & Edl. Facilities Auth. Rev., 0.06% (Williams College Proj.) Series 2006 J VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57586CPY5**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
WILLIAMS COLLEGE, MA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$31,361,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$31,361,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.61%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$31,361,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$31,361,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.06% \(Massachusetts Institute of Technology Proj.\) Series 2001 J2 VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57585KSV1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
MASSACHUSETTS INST TECH, MA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$9,770,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$9,770,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.19%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$9,770,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$9,770,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.07% \(Boston Univ. Proj.\) Series H, LOC State Street Bank & Trust Co., Boston VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575850NF5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
STATE ST BK & TR CO BOSTON	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
STATE ST BK & TR CO BOSTON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$18,920,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$18,920,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.37%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$18,920,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$18,920,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.08% \(Williams College Proj.\) Series I VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CEA9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
WILLIAMS COLLEGE, MA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$23,679,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$23,679,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.46%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$23,679,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$23,679,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.08% \(Children's Hosp. Proj.\) Series 2010 N2, LOC TD Banknorth, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586EUK5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
TD BANK NA WILMINGTON DE	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$59,400,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$59,400,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.15%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$59,400,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$59,400,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.08% \(Hallmark Health Sys. Proj.\) Series 2008 C, LOC TD Banknorth, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586ECF6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
TD BANK NA WILMINGTON DE	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$20,755,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$20,755,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.40%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$20,755,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$20,755,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.10% \(Harvard Univ. Proj.\) Series R VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57585KGP7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
-----------------------	--	--

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$37,275,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$37,275,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.72%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$37,275,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$37,275,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.10% Series 2009 O-1, LOC Fed. Home Ln. Bank of Boston VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586ELD1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
FEDERAL HOME LN BK OF BOSTON	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
FEDERAL HOME LN BK OF BOSTON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$50,745,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$50,745,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.98%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$50,745,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$50,745,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.10% \(Lowell Gen. Hosp. Proj.\) Series 2010 D, LOC JPMorgan Chase Bank VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586EXB2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$29,025,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$29,025,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.56%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$29,025,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$29,025,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.10% \(Bentley College Proj.\) Series K, LOC JPMorgan Chase Bank VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57585KLH9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$15,100,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$15,100,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.29%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$15,100,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$15,100,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.11% \(Partners HealthCare Sys., Inc. Proj.\) Series D5 VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57585K3P1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
PARTNERS HEALTHCARE SYS INC	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$6,115,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$6,115,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.12%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$6,115,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$6,115,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.11% \(Wellesley College Proj.\) Series 2008 I VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CP25](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
WELLESLEY COLLEGE, MA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$18,805,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$18,805,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.36%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$18,805,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$18,805,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.11% \(Partners HealthCare Sys., Inc. Proj.\) Series D6 VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57585K3Q9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
PARTNERS HEALTHCARE SYS INC	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$4,635,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$4,635,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.09%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$4,635,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$4,635,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Health & Edl. Facilities Auth. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Health & Edl. Facilities Auth. Rev., 0.11% Participating VRDN Series BC 10 20W, (Liquidity Facility Barclays Bank PLC)**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **06740GFN1**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BARCLAYS BANK PLC	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$5,335,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$5,335,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.10%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$5,335,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$5,335,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)
 Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.11% \(Harvard Vanguard Med. Associates Proj.\) Series 2004, LOC TD Banknorth, NA VRDN](#)
 Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CCZ6](#)
 Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
 Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
 Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)
 Brief description: (optional): [Not Provided]
 Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
 Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
 Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)
 Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)
 Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
TD BANK NA WILMINGTON DE	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
 Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,700,000.00](#)
 Item 41. The total current amortized cost, to the nearest cent: [\\$2,700,000.00](#)
 Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.05%](#)
 Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
 Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
 Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,700,000.00](#)
 Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,700,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)
 Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.11% Participating VRDN Series BC 10 15W, \(Liquidity Facility Barclays Bank PLC\)](#)
 Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [06740GFC5](#)
 Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BARCLAYS BANK PLC	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$6,500,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$6,500,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.13%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$6,500,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$6,500,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.12% \(The Henry Heywood Memorial Hosp. Issue Proj.\) Series 2009 C, LOC TD Banknorth, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586EGT2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
TD BANK NA WILMINGTON DE	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$880,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$880,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.02%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$880,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$880,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.12% \(Henry Heywood Memorial Hosp. Proj.\) Series 2008 C, LOC TD Banknorth, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586C7E9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
TD BANK NA WILMINGTON DE	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$6,370,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$6,370,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.12%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$6,370,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$6,370,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Health & Edl. Facilities Auth. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Health & Edl. Facilities Auth. Rev., 0.12% (Dana-Farber Cancer Institute Proj.) Series 2008 L1, LOC JPMorgan Chase Bank VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57586CY90**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$26,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$26,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.50%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$26,000,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$26,000,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.12% \(CIL Realty of Massachusetts Proj.\) Series 2007, LOC JPMorgan Chase Bank VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CXK6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$13,950,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$13,950,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.27%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$13,950,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$13,950,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.12% \(Baystate Health Sys. Proj.\) Series 2009 J1, LOC JPMorgan Chase Bank VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586EKC4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$12,570,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$12,570,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.24%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$12,570,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$12,570,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.13% Participating VRDN Series BBT 08 54, \(Liquidity Facility Branch Banking & Trust Co.\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [07330CQY8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BRANCH BANKING AND TRUST CO	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$12,555,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$12,555,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.24%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$12,555,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$12,555,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.13% Participating VRDN Series BBT 08 56, \(Liquidity Facility Branch Banking & Trust Co.\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [07330CSA8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BRANCH BANKING AND TRUST CO	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$15,395,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$15,395,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.30%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$15,395,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$15,395,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.14% Participating VRDN Series Clipper 07 08, \(Liquidity Facility State Street Bank & Trust Co., B](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [18886PSLO](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
STATE ST BK & TR CO BOSTON	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$11,250,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$11,250,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.22%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$11,250,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$11,250,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Health & Edl. Facilities Auth. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Health & Edl. Facilities Auth. Rev., 0.14% Participating VRDN Series Putters 3548, (Liquidity Facility JPMorgan Chase Bank)**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **46633VDN6**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$9,925,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$9,925,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.19%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$9,925,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$9,925,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.14% Participating VRDN Series Putters 3650, \(Liquidity Facility JPMorgan Chase Bank\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [46633VNX3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$11,800,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$11,800,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.23%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$11,800,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$11,800,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.14% Participating VRDN Series Putters 3529, \(Liquidity Facility JPMorgan Chase Bank\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [46633VBP3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$26,660,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$26,660,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.52%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$26,660,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$26,660,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Health & Edl. Facilities Auth. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Health & Edl. Facilities Auth. Rev., 0.14% Participating VRDN Series Putters 3531, (Liquidity Facility JPMorgan Chase Bank)**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **46633VBT5**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$12,495,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$12,495,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.24%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$12,495,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$12,495,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.14% Participating VRDN Series Putters 3530, \(Liquidity Facility JPMorgan Chase Bank\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [46633VBR9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$1,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.02%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$1,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$1,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.14% Participating VRDN Series Putters 3104, \(Liquidity Facility JPMorgan Chase Bank\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586C8Q1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$3,550,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$3,550,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.07%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$3,550,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$3,550,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.14% Participating VRDN Series PT 4633, \(Liquidity Facility Deutsche Postbank AG\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [74703XDV1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
DEUTSCHE POSTBANK AG	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$25,730,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$25,730,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.50%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$25,730,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$25,730,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.15% \(Children's Hosp. Proj.\) Series 2010 N4, LOC JPMorgan Chase Bank VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586EUJ8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$17,650,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$17,650,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.34%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$17,650,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$17,650,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.15% \(Baystate Health Sys. Proj.\) Series 2009 J2, LOC JPMorgan Chase Bank VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586EKB6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
-----------------------	--	--

JPMORGAN CHASE BANK NA	N/A	N/A
------------------------	-----	-----

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$13,550,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$13,550,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.26%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$13,550,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$13,550,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.15% \(Northeast Hosp. Corp. Proj.\) Series 2004 G, LOC JPMorgan Chase Bank VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CDV4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$37,600,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$37,600,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.73%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$37,600,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$37,600,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Health & Edl. Facilities Auth. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Health & Edl. Facilities Auth. Rev., 0.16% (Southcoast Health Sys. Obligated Group Proj.) Series 2008 C, LOC Bank of America NA VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57586C6T7**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$15,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$15,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.29%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$15,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$15,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.16% \(Winchester Hosp. Proj.\) Series 2004 F, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CDD4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$15,170,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$15,170,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.29%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$15,170,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$15,170,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.17% \(Baystate Med. Ctr. Proj.\) Series 2005 G, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CNH4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$17,005,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$17,005,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.33%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$17,005,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$17,005,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.20% \(Northeast Hosp. Corp. Proj.\) Series 2006 H, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CQJ7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$23,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$23,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.45%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$23,000,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$23,000,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.20% Participating VRDN Series BA 08 3320, \(Liquidity Facility Bank of America NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [05248RBS9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$2,810,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$2,810,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.05%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$2,810,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$2,810,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Health & Edl. Facilities Auth. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Health & Edl. Facilities Auth. Rev., 0.20% (Peabody Essex Museum Proj.) Series 2002, LOC Bank of America NA VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57585KS25**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$15,025,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$15,025,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.29%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$15,025,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$15,025,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.20% \(Mount Indl. Dev. Auth. College Proj.\) Series 2007 A, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CYF6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$1,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.02%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$1,000,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$1,000,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.24% Participating VRDN Series BA 08 1056, \(Liquidity Facility Bank of America NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [05248PSU0](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$3,290,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$3,290,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.06%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$3,290,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$3,290,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.25% \(Endicott College Proj.\) Series 2004 D, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CCV5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$23,065,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$23,065,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.45%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$23,065,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$23,065,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.25% \(Endicott College Proj.\) Series 2007 E, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CM51](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$12,550,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$12,550,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.24%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$12,550,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$12,550,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.27% \(Fairview Extended Care Proj.\) Series B, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57585JRR4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$27,800,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$27,800,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.54%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$27,800,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$27,800,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Hsg. Fin. Agcy. Hsg. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Hsg. Fin. Agcy. Hsg. Rev., 0.15% Series 2004 A, LOC Lloyds TSB Bank PLC VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57586PHE9**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
LLOYDS TSB BANK PLC (UNGTD)	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
LLOYDS TSB BANK PLC (UNGTD)	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$28,345,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$28,345,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.55%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$28,345,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$28,345,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Hsg. Fin. Agcy. Multi-Family Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Hsg. Fin. Agcy. Multi-Family Rev., 0.15% \(Princeton Crossing LP Proj.\) Series 1996 A, LOC Fannie Mae Mtg. pass-thru certificates VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [5758545T7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
FANNIE MAE	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
FANNIE MAE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$20,300,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$20,300,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.39%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$20,300,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$20,300,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Indl. Fin. Agcy. Indl. Dev. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Indl. Fin. Agcy. Indl. Dev. Rev., 0.40% \(Decas Cranberry Proj.\) Series 1997, LOC TD Banknorth, NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575855S77](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
TD BANK NA WILMINGTON DE	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,250,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,250,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.04%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,250,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,250,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Indl. Fin. Agcy. Indl. Dev. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Indl. Fin. Agcy. Indl. Dev. Rev., 0.50% \(United Plastics Proj.\) Series 1997, LOC Wells Fargo Bank NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575855S44](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
WELLS FARGO BK NATL ASSN	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
WELLS FARGO BK NATL ASSN	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,380,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$1,380,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.03%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$1,380,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$1,380,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Indl. Fin. Agcy. Indl. Dev. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Indl. Fin. Agcy. Indl. Dev. Rev., 0.55% \(Boutwell Owens & Co., Inc. Proj.\) Series 1998, LOC Wells Fargo Bank NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575855V73](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
WELLS FARGO BK NATL ASSN	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
WELLS FARGO BK NATL ASSN	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$560,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$560,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.01%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$560,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$560,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Indl. Fin. Agcy. Indl. Dev. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Indl. Fin. Agcy. Indl. Dev. Rev., 0.60% \(346 Univ. LLC Proj.\) Series 1996, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575855P96](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$1,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$1,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.02%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$1,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$1,000,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Indl. Fin. Agcy. Indl. Dev. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Indl. Fin. Agcy. Indl. Dev. Rev., 0.90% (Brady Enterprises Proj.) Series 1996, LOC Bank of America NA VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **575855R86**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$1,250,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$1,250,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.02%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$1,250,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$1,250,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Indl. Fin. Agcy. Indl. Dev. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Indl. Fin. Agcy. Indl. Dev. Rev., 0.90% \(BBB Esq. LLC Proj.\) Series 1996, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575855S28](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$1,900,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$1,900,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.04%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$1,900,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$1,900,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Port Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Port Auth. Rev., 0.13% Participating VRDN Series Solar 06 108, \(Liquidity Facility U.S. Bank NA, Minnesota\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [27884FKJ8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
US BANK NA CINCINNATI OHIO	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$14,205,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$14,205,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.28%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$14,205,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$14,205,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Port Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Port Auth. Rev., 0.14% Series 2010 D, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575896JD8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$90,305,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$90,305,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.75%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$90,305,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$90,305,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Port Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Port Auth. Rev., 0.17% Series 2008 A, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575896ET8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$11,700,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$11,700,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.23%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$11,700,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$11,700,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Port Auth. Spl. Proj. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Port Auth. Spl. Proj. Rev., 0.17% \(Harborside Hyatt Proj.\) Series 2001 A, LOC Royal Bank of Scotland PLC VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575897AC7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
ROYAL BANK OF SCOTLAND PLC	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
ROYAL BANK OF SCOTLAND PLC	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$37,100,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$37,100,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.72%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$37,100,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$37,100,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.13% Participating VRDN Series Solar 05 03, \(Liquidity Facility U.S. Bank NA, Minnesota\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [27884FAE0](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
US BANK NA CINCINNATI OHIO	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$20,230,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$20,230,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.39%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$20,230,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$20,230,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.14% Participating VRDN Series EGL 07 0067, \(Liquidity Facility Citibank NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [576000GM9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$41,660,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$41,660,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.81%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$41,660,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$41,660,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.14% Participating VRDN Series EGL 07 0032, \(Liquidity Facility Citibank NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [576000FN8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$69,300,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$69,300,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.34%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$69,300,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$69,300,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.14% Participating VRDN Series ROC II R 12254, \(Liquidity Facility Citibank NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [576000KF9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

- Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$14,000,000.00**
- Item 41. The total current amortized cost, to the nearest cent: **\$14,000,000.00**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.27%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$14,000,000.00**
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$14,000,000.00**

Security

- Item 26. The name of the issuer: **Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.**
- Item 27. The title of the issue (including coupon or yield): **Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.14% Participating VRDN Series Putters 2479Z, (Liquidity Facility JPMorgan Chase Bank)**
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **576000JJ3**
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**
- Brief description: (optional): **[Not Provided]**
- Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**
- Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**
- Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

- Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**
- Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**
- Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

- Item 38. Does the security have a Guarantee? **No**
- Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**
- Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$2,340,000.00**
- Item 41. The total current amortized cost, to the nearest cent: **\$2,340,000.00**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.05%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$2,340,000.00**
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$2,340,000.00**

Security

Item 26. The name of the issuer: [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.14% Participating VRDN Series EGL 07 0092, \(Liquidity Facility Citibank NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [576000GT4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$46,095,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$46,095,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.89%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$46,095,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$46,095,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.14% Participating VRDN Series Putters 1197, \(Liquidity Facility Deutsche Bank AG New York\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [576000CZ4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
DEUTSCHE BANK AG NEW YORK BNCH	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$990,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$990,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.02%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$990,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$990,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.14% Participating VRDN Series Putters 1185, \(Liquidity Facility Deutsche Bank AG New York](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [576000CX9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
-----------------------	--	--

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$10,130,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$10,130,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.20%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$10,130,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$10,130,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.14% Participating VRDN ROC II R 12193, \(Liquidity Facility Citibank NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [576000JB0](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$8,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$8,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.16%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$8,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$8,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.14% Participating VRDN Series EGL 07 0031, \(Liquidity Facility Citibank NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [576000FL2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$47,600,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$47,600,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.92%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$47,600,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$47,600,000.00**

Security

Item 26. The name of the issuer: [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.15% Participating VRDN Series MS 3228X, \(Liquidity Facility Morgan Stanley Bank, West Val](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [576000KX0](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
MORGAN STANLEY BK NA SALT LAKE	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,500,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,500,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.05%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,500,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,500,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.15% Participating VRDN Series Putters 3691, \(Liquidity Facility JPMorgan Chase Bank\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [46633VRV3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,100,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,100,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.04%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,100,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,100,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.20% Participating VRDN Series BA 08 1082, \(Liquidity Facility Bank of America NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [05248PVN2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$7,020,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$7,020,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.14%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$7,020,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$7,020,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts School Bldg. Auth. Dedicated Sales Tax Rev., 0.24% Participating VRDN Series BA 08 3307, \(Liquidity Facility Bank of America NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [05248P3N3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$5,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$5,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.10%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$5,000,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$5,000,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts St Wtr. Resources Auth.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts St Wtr. Resources Auth., 0.14% Participating VRDN Series Putters 3690, \(Liquidity Facility JPMorgan Chase Bank\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [46633VRT8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,300,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$1,300,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.03%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$1,300,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$1,300,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Poll. Abatement Trust](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Poll. Abatement Trust, 0.13% Participating VRDN Series BBT 08 40, \(Liquidity Facility Branch Banking & Trust Co.\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [07330CNT2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BRANCH BANKING AND TRUST CO	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$15,400,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$15,400,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.30%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$15,400,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$15,400,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Poll. Abatement Trust](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Poll. Abatement Trust, 0.14% Participating VRDN Series Putters 3159, \(Liquidity Facility JPMorgan Chase Bank\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [46632PEK5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
-----------------------	--	--

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$15,490,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$15,490,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.30%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$15,490,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$15,490,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Poll. Abatement Trust](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Poll. Abatement Trust, 0.14% Participating VRDN Series PT 4644, \(Liquidity Facility Deutsche Postbank AG\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [74703YLP3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
DEUTSCHE POSTBANK AG	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$11,225,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$11,225,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.22%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$11,225,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$11,225,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Poll. Abatement Trust](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Poll. Abatement Trust, 0.17% Participating VRDN Series Clipper 06 11, \(Liquidity Facility State Street Bank & Trust Co., Boston\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [18886PPV1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
STATE ST BK & TR CO BOSTON	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$23,900,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$23,900,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.46%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$23,900,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$23,900,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev., 0.06% Series 2008 F, \(Liquidity Facility Bank of Nova Scotia New York Branch\) VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [5760494W7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF NOVA SCOTIA NY BRH	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$76,355,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$76,355,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.48%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$76,355,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$76,355,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev., 0.11% Series 2008 E, \(Liquidity Facility JPMorgan Chase Bank\) VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [5760494U1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$57,370,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$57,370,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.11%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$57,370,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$57,370,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev., 0.13% Participating VRDN Series Solar 06 86, \(Liquidity Facility U.S. Bank NA, Minnesota\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [27884FHL7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
US BANK NA CINCINNATI OHIO	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

- Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$21,920,000.00](#)
- Item 41. The total current amortized cost, to the nearest cent: [\\$21,920,000.00](#)
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.43%](#)
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$21,920,000.00](#)
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$21,920,000.00](#)

Security

- Item 26. The name of the issuer: [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev.](#)
- Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev., 0.14% Participating VRDN Series Putters 2848, \(Liquidity Facility JPMorgan Chase Bank\)](#)
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [5760494N7](#)
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)
- Brief description: (optional): [Not Provided]
- Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
- Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
- Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

- Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)
- Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)
- Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

- Item 38. Does the security have a Guarantee? [No](#)
- Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
- Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$19,075,000.00](#)
- Item 41. The total current amortized cost, to the nearest cent: [\\$19,075,000.00](#)
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.37%](#)
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$19,075,000.00](#)
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$19,075,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev., 0.14% Participating VRDN Series EGL 06 0054, \(Liquidity Facility Citibank NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [576049S35](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$4,300,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$4,300,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.08%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$4,300,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$4,300,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev., 0.14% Participating VRDN Series ROC II R 11968, \(Liquidity Facility Citibank NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [576051DR4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,185,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,185,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.04%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,185,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,185,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev., 0.14% Participating VRDN Series ROC II R 11914, \(Liquidity Facility Citibank NA\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [576051BT2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$1,760,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$1,760,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.03%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$1,760,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$1,760,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev., 0.14% Participating VRDN Series EGL 7050011 Class A, (Liquidity Facility Citibank NA)**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **576049K66**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
CITIBANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$10,990,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$10,990,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.21%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$10,990,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$10,990,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev.](#)
Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev., 0.17% Participating VRDN Series Putters 3911, \(Liquidity Facility JPMorgan Chase Bank\)](#)
Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [46633VY94](#)
Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)
Brief description: (optional): [Not Provided]
Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)
Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)
Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
JPMORGAN CHASE BANK NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)
Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$6,665,000.00](#)
Item 41. The total current amortized cost, to the nearest cent: [\\$6,665,000.00](#)
Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.13%](#)
Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$6,665,000.00](#)
Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$6,665,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev.](#)
Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev., 0.18% Series 2008 B, \(Liquidity Facility Bank of America NA\) VRDN](#)
Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [5760494X5](#)
Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$60,430,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$60,430,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.17%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$60,430,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$60,430,000.00](#)

Security

Item 26. The name of the issuer: [Univ. of Massachusetts Bldg. Auth. Facilities Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Univ. of Massachusetts Bldg. Auth. Facilities Rev., 0.17% Series 2008 1, LOC Lloyds TSB Bank PLC VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [914440HE5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
LLOYDS TSB BANK PLC (UNGTD)	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
LLOYDS TSB BANK PLC (UNGTD)	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$141,320,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$141,320,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [2.74%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$141,320,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$141,320,000.00](#)

Security

Item 26. The name of the issuer: [Puerto Rico Commonwealth Hwy. & Trans. Auth. Trans. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Puerto Rico Commonwealth Hwy. & Trans. Auth. Trans. Rev., 0.11% Series 1998 A, LOC Bank of Nova Scotia New York Branch VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [745190Y77](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF NOVA SCOTIA NY BRH	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$64,165,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$64,165,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.24%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$64,165,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$64,165,000.00**

Security

Item 26. The name of the issuer: **Puerto Rico Commonwealth Pub. Impt. Gen. Oblig.**

Item 27. The title of the issue (including coupon or yield): **Puerto Rico Commonwealth Pub. Impt. Gen. Oblig., 0.10% Series 2003 C5-2, LOC Barclays Bank PLC NY Branch VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **74514LYU5**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BARCLAYS BANK PLC NY BRANCH	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BARCLAYS BANK PLC NY BRANCH	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$51,900,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$51,900,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **1.01%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$51,900,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$51,900,000.00**

Security

Item 26. The name of the issuer: **Colorado Reg'l. Trans. District Sales Tax Rev.**

Item 27. The title of the issue (including coupon or yield): **Colorado Reg'l. Trans. District Sales Tax Rev., 0.20% Participating VRDN Series MT 741, (Liquidity Facility Bank of America NA)**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **74703Y3L2**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$13,300,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$13,300,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.26%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$13,300,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$13,300,000.00**

Security

Item 26. The name of the issuer: **Ohio Hsg. Fin. Agcy. Mtg. Rev.**

Item 27. The title of the issue (including coupon or yield): **Ohio Hsg. Fin. Agcy. Mtg. Rev., 1.00% (Mtg.-Backed Securities Prog.) Series 2007 E, (Liquidity Facility KBC Bank NV) VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [676907QC5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
KBC BANK NV	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	OH RESIDENTIAL MORT REV 6/1/94	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$10,800,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$10,800,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.21%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$10,800,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$10,800,000.00](#)

Security

Item 26. The name of the issuer: [Maine Pub. Util. Fin. Pub. Util. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Maine Pub. Util. Fin. Pub. Util. Rev., 0.47% \(Maine Pub. Svc. Co. Proj.\) Series 2000, LOC Bank of America NA VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [560488AC2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
BANK OF AMERICA NA	N/A	N/A

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF AMERICA NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$9,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$9,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.17%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$9,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$9,000,000.00**

Security

Item 26. The name of the issuer: **Michigan City Ltd. Oblig. Rev.**

Item 27. The title of the issue (including coupon or yield): **Michigan City Ltd. Oblig. Rev., 0.24% (Palatek Proj.) LOC Comerica Bank VRDN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **594316AA9**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Variable Rate Demand Note**

Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-07**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-07**

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
COMERICA BK DALLAS TEX	N/A	N/A

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
COMERICA BK DALLAS TEX	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$4,420,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$4,420,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.09%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$4,420,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$4,420,000.00](#)

Security

Item 26. The name of the issuer: [Delaware Econ. Dev. Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Delaware Econ. Dev. Auth. Rev., 0.40% \(Delmarva Pwr. & Lt. Co. Proj.\) Series 1999 A VRDN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [246387JQ8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Variable Rate Demand Note](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Second Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [Yes](#)

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
DELMARVA POWER & LIGHT	N/A	N/A

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

- Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$4,300,000.00**
- Item 41. The total current amortized cost, to the nearest cent: **\$4,300,000.00**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.08%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$4,300,000.00**
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$4,300,000.00**

Security

- Item 26. The name of the issuer: **Billerica Gen. Oblig.**
- Item 27. The title of the issue (including coupon or yield): **Billerica Gen. Oblig., 1.50% BAN**
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **0900596D3**
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Municipal Debt**
Brief description: (optional): **[Not Provided]**
- Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**
- Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**
- Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

- | | |
|--|--|
| | |
|--|--|
- Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2012-05-18**
- Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2012-05-18**
- Item 37. Does the security have a Demand Feature? **No**
- Item 38. Does the security have a Guarantee? **No**
- Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**
- Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$5,900,000.00**
- Item 41. The total current amortized cost, to the nearest cent: **\$5,932,545.79**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.12%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$5,938,291.00**
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$5,938,291.00**

Security

- Item 26. The name of the issuer: **Billerica Gen. Oblig.**
- Item 27. The title of the issue (including coupon or yield): **Billerica Gen. Oblig., 1.50% BAN**
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **0900596E1**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-08-10](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-08-10](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$10,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$10,090,109.07](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.20%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$10,089,600.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$10,089,600.00](#)

Security

Item 26. The name of the issuer: [Boston Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Boston Gen. Oblig., 2.50% Bonds Series 2011 A](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [100853MM9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-04-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-04-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

- Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$6,055,000.00**
- Item 41. The total current amortized cost, to the nearest cent: **\$6,107,882.98**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.12%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$6,112,704.15**
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$6,112,704.15**

Security

- Item 26. The name of the issuer: **Boston Gen. Oblig.**
- Item 27. The title of the issue (including coupon or yield): **Boston Gen. Oblig., 5.00% Bonds Series 2008 A**
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **100853DS6**
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Municipal Debt**
Brief description: (optional): **[Not Provided]**
- Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**
- Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **Second Tier Security**
- Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

- | | |
|--|--|
| | |
|--|--|
- Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2012-04-01**
- Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2012-04-01**
- Item 37. Does the security have a Demand Feature? **No**
- Item 38. Does the security have a Guarantee? **No**
- Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**
- Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$2,575,000.00**
- Item 41. The total current amortized cost, to the nearest cent: **\$2,626,422.75**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.05%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$2,626,422.75**
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$2,626,422.75**

Security

- Item 26. The name of the issuer: **Burlington Gen. Oblig.**
- Item 27. The title of the issue (including coupon or yield): **Burlington Gen. Oblig., 1.50% BAN**
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **121835YM8**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-07-27](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-07-27](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$13,326,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$13,446,077.45](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.26%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$13,441,802.94](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$13,441,802.94](#)

Security

Item 26. The name of the issuer: [Chatham Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Chatham Gen. Oblig., 1.25% BAN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [162105TU4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-06-29](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-06-29](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

- Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$11,977,000.00](#)
- Item 41. The total current amortized cost, to the nearest cent: [\\$12,058,941.54](#)
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.23%](#)
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$12,059,162.22](#)
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$12,059,162.22](#)

Security

- Item 26. The name of the issuer: [Chatham Gen. Oblig.](#)
- Item 27. The title of the issue (including coupon or yield): [Chatham Gen. Oblig., 1.50% BAN](#)
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [162105TT7](#)
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]
- Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
- Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
- Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

- | |
|--|
| Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): 2012-06-29 |
| Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: 2012-06-29 |
| Item 37. Does the security have a Demand Feature? No |
| Item 38. Does the security have a Guarantee? No |
| Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? No |
| Item 40. The total principal amount of the security held by the series, to the nearest cent: \$34,700,000.00 |
| Item 41. The total current amortized cost, to the nearest cent: \$34,987,081.18 |
| Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: 0.68% |
| Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security: |
| Item 44. Is this an Illiquid Security as of the date of this report? No |
| Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: \$34,995,297.00 |
| Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: \$34,995,297.00 |

Security

- Item 26. The name of the issuer: [Concord Gen. Oblig.](#)
- Item 27. The title of the issue (including coupon or yield): [Concord Gen. Oblig., 1.50% BAN](#)
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [206273B52](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-05-31](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-05-31](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,675,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,694,555.17](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.05%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,694,527.50](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,694,527.50](#)

Security

Item 26. The name of the issuer: [Dev. Fin. Agcy.](#)

Item 27. The title of the issue (including coupon or yield): [Dev. Fin. Agcy., 0.22% Series 2001, LOC TD Banknorth, NA, CP](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [57563P9D7](#)

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-04](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-04](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
TD BANK NA WILMINGTON DE	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$8,624,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$8,624,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.17%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$8,624,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$8,624,000.00**

Security

Item 26. The name of the issuer: **Duxbury Gen. Oblig.**

Item 27. The title of the issue (including coupon or yield): **Duxbury Gen. Oblig., 1.50% BAN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **267399TX1**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Municipal Debt**
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **Unrated Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2012-06-28**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2012-06-28**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$2,665,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$2,684,135.29**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.05%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$2,684,747.65**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$2,684,747.65**

Security

Item 26. The name of the issuer: [Framingham Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Framingham Gen. Oblig., 2.00% Bonds](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [351694P99](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-06-15](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-06-15](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$3,697,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$3,736,109.90](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.07%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$3,736,594.87](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$3,736,594.87](#)

Security

Item 26. The name of the issuer: [Gloucester Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Gloucester Gen. Oblig., 1.00% BAN Series A](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [3797128B1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-03-16](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-03-16](#)

Item 37. Does the security have a Demand Feature? [No](#)
Item 38. Does the security have a Guarantee? [No](#)
Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$12,818,317.00](#)
Item 41. The total current amortized cost, to the nearest cent: [\\$12,852,703.90](#)
Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.25%](#)
Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$12,852,926.46](#)
Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$12,852,926.46](#)

Security

Item 26. The name of the issuer: [Grafton Gen. Oblig.](#)
Item 27. The title of the issue (including coupon or yield): [Grafton Gen. Oblig., 2.00% BAN](#)
Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [384406LC6](#)
Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]
Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-04-12](#)
Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-04-12](#)
Item 37. Does the security have a Demand Feature? [No](#)
Item 38. Does the security have a Guarantee? [No](#)
Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$10,000,000.00](#)
Item 41. The total current amortized cost, to the nearest cent: [\\$10,065,556.28](#)
Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.20%](#)
Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$10,074,900.00](#)
Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$10,074,900.00](#)

Security

Item 26. The name of the issuer: [Haverhill Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Haverhill Gen. Oblig., 1.50% BAN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [4195064S6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$7,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$7,005,782.19](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.14%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$7,006,440.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$7,006,440.00](#)

Security

Item 26. The name of the issuer: [Marblehead Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Marblehead Gen. Oblig., 1.50% BAN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [566081SE6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-08-10](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-08-10](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$6,596,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$6,658,512.87](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.13%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$6,658,200.28](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$6,658,200.28](#)

Security

Item 26. The name of the issuer: [Marlborough Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Marlborough Gen. Oblig., 1.50% BAN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [570884P83](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-06-20](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-06-20](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$4,350,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$4,382,965.35](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.09%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$4,384,495.50](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$4,384,495.50](#)

Security

Item 26. The name of the issuer: [Massachusetts Bay Trans. Auth. Sales Tax Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Bay Trans. Auth. Sales Tax Rev., 5.00% Bonds Series C](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575579SC2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-07-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-07-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,600,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$1,650,509.59](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.03%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$1,650,384.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$1,650,384.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dept. of Trans. Metropolitan Hwy. Sys. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dept. of Trans. Metropolitan Hwy. Sys. Rev., 4.00% Bonds Series B](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57563CBK7](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	MASSACHUSETTS ST TPK AUTH MET	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$6,350,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$6,382,722.76](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.12%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$6,384,544.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$6,384,544.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Electrical Utils. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Electrical Utils. Rev., 0.65% Bonds \(Nantucket Elec. Co. Proj.\) Series 2005, tender 11/30/2011, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57584GAC2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Second Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-30](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-30](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	NANTUCKET ELEC CO	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$3,600,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$3,600,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.07%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$3,600,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$3,600,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 0.18% Series 2001, LOC JPMorgan Chase Bank, CP](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [08R99MDG9](#)

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-07](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
JPMORGAN CHASE BANK NA	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$9,950,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$9,950,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.19%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$9,950,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$9,950,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Dev. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Dev. Fin. Agcy. Rev., 5.00% Bonds Series R1](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583R3R4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-07-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-07-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	BOSTON COLLEGE,MA	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$1,031,853.78](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.02%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$1,031,490.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$1,031,490.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Fed. Hwy.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Fed. Hwy., 0.00% Bonds Series 2011 B, \(Escrowed to Maturity\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57583PBZ1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-06-15](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-06-15](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$998,443.10](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.02%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$996,800.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$996,800.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 0.14% Bonds Series 2011 A](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57582PWT3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-03](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-03](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$13,800,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$13,800,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.27%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$13,800,276.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$13,800,276.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 2.00% Bonds Series 2011 B](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57582PWY2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$5,875,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$5,891,314.47](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.11%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$5,892,390.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$5,892,390.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 3.00% Bonds Series 2009 B](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57582PRF9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-07-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-07-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,150,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,188,902.64](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.04%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,189,323.50](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,189,323.50](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 4.00% Bonds Series 2011 B](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57582PA42](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-10-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-10-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$39,925,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$41,307,795.34](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.80%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$41,294,028.25](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$41,294,028.25](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 5.00% Bonds Series 2006 A](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57582N5D3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-07-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-07-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,925,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$1,985,966.10](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.04%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$1,985,618.25](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$1,985,618.25](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 5.00% Bonds Series 1995 A](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575826MM1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-07-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-07-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,395,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$1,439,322.58](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.03%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$1,438,830.90](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$1,438,830.90](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 5.50% Bonds Series 2002 C](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57582NDH5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,435,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,435,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.05%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,435,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,435,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 5.50% Bonds Series C](#)
Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [5758273X6](#)
Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]
Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)
Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-01](#)
Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-01](#)
Item 37. Does the security have a Demand Feature? [No](#)
Item 38. Does the security have a Guarantee? [No](#)
Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,155,000.00](#)
Item 41. The total current amortized cost, to the nearest cent: [\\$2,164,047.67](#)
Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.04%](#)
Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,163,986.35](#)
Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,163,986.35](#)

Security

Item 26. The name of the issuer: [Massachusetts Gen. Oblig.](#)
Item 27. The title of the issue (including coupon or yield): [Massachusetts Gen. Oblig., 6.00% Bonds Series 1996 A](#)
Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575827EG1](#)
Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]
Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)
Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-01](#)
Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-01](#)
Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$5,575,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$5,575,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.11%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$5,575,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$5,575,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.10% Series EE, CP](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [00N992JS2](#)

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the aquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-02](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-02](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PRESIDENT & FELLOWS HARVARD CO	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$90,725,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$90,725,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [1.76%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$90,725,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$90,725,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.10% Series EE, CP](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [00N992JF0](#)

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-02](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-02](#)

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **Yes**

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PRESIDENT & FELLOWS HARVARD CO	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$13,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$13,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.25%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$13,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$13,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.10% Series EE, CP](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [00N992JK9](#)

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-02](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-02](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PRESIDENT & FELLOWS HARVARD CO	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$15,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$15,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.29%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$15,000,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$15,000,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.10% Series EE, CP](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [00N992JN3](#)

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PRESIDENT & FELLOWS HARVARD CO	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$8,500,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$8,500,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.16%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$8,500,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$8,500,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.10% Series EE, CP](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [00N992JM5](#)

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-14](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-14](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
---------------------	----------------------	---	---

OBLIGOR	PRESIDENT & FELLOWS HARVARD CO	N/A	N/A
---------	--------------------------------------	-----	-----

- Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$30,325,000.00](#)
- Item 41. The total current amortized cost, to the nearest cent: [\\$30,325,000.00](#)
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.59%](#)
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$30,325,000.00](#)
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$30,325,000.00](#)

Security

- Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)
- Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.10% Series EE, CP](#)
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [00N992JR4](#)
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]
- Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
- Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
- Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

- Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-17](#)
- Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-17](#)
- Item 37. Does the security have a Demand Feature? [No](#)
- Item 38. Does the security have a Guarantee? [No](#)
- Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PRESIDENT & FELLOWS HARVARD CO	N/A	N/A

- Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,000,000.00](#)
- Item 41. The total current amortized cost, to the nearest cent: [\\$1,000,000.00](#)
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.02%](#)
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$1,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$1,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.11% Series EE, CP](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [00N992JG8](#)

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **Yes**

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PRESIDENT & FELLOWS HARVARD CO	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$10,981,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$10,981,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.21%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$10,981,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$10,981,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.11% Series EE, CP](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [00N992JP8](#)

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-06](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-06](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PRESIDENT & FELLOWS HARVARD CO	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$12,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$12,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.23%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$12,000,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$12,000,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.14% Bonds \(Partners Healthcare Sys., Inc. Proj.\) Series 2008 H1, tender 11/07/2011, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CV93](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PARTNERS HEALTHCARE SYS INC	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$5,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$5,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.10%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$5,000,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$5,000,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.14% Bonds \(Partners Healthcare Sys., Inc. Proj.\) Series 2008 H1, tender 11/07/2011, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CV93](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
---------------------	----------------------	---	---

OBLIGOR	PARTNERS HEALTHCARE SYS INC	N/A	N/A
---------	-----------------------------------	-----	-----

- Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$2,660,000.00**
- Item 41. The total current amortized cost, to the nearest cent: **\$2,660,000.00**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.05%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$2,660,000.00**
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$2,660,000.00**

Security

- Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)
- Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.15% Bonds \(Partners Healthcare Sys., Inc. Proj.\) Series 2008 H1, tender 11/03/2011, CP Mode](#)
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CV93](#)
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]
- Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**
- Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
- Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

- Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-03**
- Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-03**
- Item 37. Does the security have a Demand Feature? **No**
- Item 38. Does the security have a Guarantee? **No**
- Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **Yes**

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PARTNERS HEALTHCARE SYS INC	N/A	N/A

- Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$12,500,000.00**
- Item 41. The total current amortized cost, to the nearest cent: **\$12,500,000.00**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.24%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$12,500,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$12,500,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.15% Bonds \(Partners HealthCare Sys. Proj.\) Series 2008 H2, tender 02/06/2012, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CW27](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-02-06](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-02-06](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PARTNERS HEALTHCARE SYS INC	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$19,790,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$19,790,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.38%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$19,790,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$19,790,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.16% Bonds \(Partners HealthCare Sys. Proj.\) Series 2008 H1, tender 03/01/2012, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CV93](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-03-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-03-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PARTNERS HEALTHCARE SYS INC	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$8,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$8,000,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.16%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$8,000,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$8,000,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.17% Bonds \(Partners HealthCare Sys., Inc. Proj.\) Series 2008 H2, tender 02/03/2012, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CW27](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-02-03](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-02-03](#)

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **Yes**

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PARTNERS HEALTHCARE SYS INC	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$14,040,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$14,040,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.27%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$14,040,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$14,040,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Health & Edl. Facilities Auth. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Health & Edl. Facilities Auth. Rev., 0.17% Bonds (Partners HealthCare Sys., Inc. Proj.) Series 2008 H2, tender 02/08/2012, CP Mode**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57586CW27**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Municipal Debt**
Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2012-02-08**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2012-02-08**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **Yes**

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PARTNERS HEALTHCARE SYS INC	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$19,790,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$19,790,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.38%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$19,790,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$19,790,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.18% Bonds \(Partners Healthcare Sys., Inc. Proj.\) Series 2008 H1, tender 12/06/2011, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CV93](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-06](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-06](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PARTNERS HEALTHCARE SYS INC	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,600,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,600,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.05%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,600,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,600,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.18% Bonds \(Partners Healthcare Sys., Inc. Proj.\) Series 2008 H1, tender 12/06/2011, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CV93](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-06](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-06](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PARTNERS HEALTHCARE SYS INC	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$12,500,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$12,500,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.24%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$12,500,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$12,500,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.22% Bonds \(Partners HealthCare Sys. Proj.\) Series 2008 H2, tender 01/05/2012, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CW27](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-05](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-05](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PARTNERS HEALTHCARE SYS INC	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$7,020,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$7,020,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.14%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$7,020,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$7,020,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.23% Bonds \(Partners HealthCare Sys. Proj.\) Series 2008 H1, tender 02/09/2012, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CV93](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-02-09](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-02-09](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PARTNERS HEALTHCARE SYS INC	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$10,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$10,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.19%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$10,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$10,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Health & Edl. Facilities Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Health & Edl. Facilities Auth. Rev., 0.24% Bonds \(Partners HealthCare Sys. Proj.\) Series 2008 H1, tender 02/09/2012, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57586CV93](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-02-09](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-02-09](#)

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **Yes**

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	PARTNERS HEALTHCARE SYS INC	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$10,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$10,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.19%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$10,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$10,000,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Health & Edl. Facilities Auth. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Health & Edl. Facilities Auth. Rev., 4.13% Bonds (Northeastern Univ. Proj.) Series 2009 T1, tender 02/16/2012**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **57586EGW5**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Municipal Debt**
Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2012-02-16**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2012-02-16**

Item 37. Does the security have a Demand Feature? **Yes**

Demand Feature issuer	Designated NRSRO(s) for the Demand Feature or provider of the Demand Feature	Credit rating of the Demand Feature issuer
NORTHEASTERN UNIV MA REV	N/A	N/A

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$24,550,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$24,819,173.95**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.48%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$24,820,295.50**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$24,820,295.50**

Security

Item 26. The name of the issuer: **Massachusetts Indl. Fin. Agcy. Poll. Cont. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Indl. Fin. Agcy. Poll. Cont. Rev., 0.60% Bonds (New England Pwr. Co. Proj.) Series 1992 tender 11/22/2011, CP Mode**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **575856BE8**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Second Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-22](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-22](#)

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **Yes**

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	NEW ENGLAND POWER CO	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$7,660,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$7,660,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.15%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$7,660,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$7,660,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Indl. Fin. Agcy. Poll. Cont. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Indl. Fin. Agcy. Poll. Cont. Rev., 0.70% Bonds \(New England Pwr. Co. Proj.\) Series 1993 B, tender 11/18/2011, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575856BG3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Second Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-18](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-18](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	NEW ENGLAND POWER CO	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,020,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,020,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.04%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,020,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,020,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Indl. Fin. Agcy. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Indl. Fin. Agcy. Rev., 5.50% Bonds \(Tufts Univ. Proj.\) Series H](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575925MV1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-02-15](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-02-15](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	TUFTS UNIV, MA	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,265,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,298,478.75](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.04%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,298,771.15](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,298,771.15](#)

Security

Item 26. The name of the issuer: [Massachusetts Muni. Wholesale Elec. Co. Pwr. Supply Sys. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Muni. Wholesale Elec. Co. Pwr. Supply Sys. Rev., 5.25% Bonds \(Nuclear #4 Proj.\) Series A](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575765VC3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-07-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-07-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$8,510,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$8,665,443.17](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.17%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$8,660,371.70](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$8,660,371.70](#)

Security

Item 26. The name of the issuer: [Massachusetts Muni. Wholesale Elec. Co. Pwr. Supply Sys. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Muni. Wholesale Elec. Co. Pwr. Supply Sys. Rev., 5.25% Bonds \(Nuclear Mix #1 Proj.\) Series A](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575765UP5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-07-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-07-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$8,000,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$8,146,127.54](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.16%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$8,141,360.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$8,141,360.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Port Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Port Auth. Rev., 0.15% Series 2003 A, LOC Bank of New York, New York, CP](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [57599LDD9](#)

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-08](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-08](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF NEW YORK MELLON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$5,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$5,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.10%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$5,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$5,000,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Port Auth. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Port Auth. Rev., 0.16% Series 2003 A, LOC Bank of New York, New York, CP**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **57599LDK3**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Municipal Debt**
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2012-01-10**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2012-01-10**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF NEW YORK MELLON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$5,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$5,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.10%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$5,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$5,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Port Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Port Auth. Rev., 0.18% Series 2003 B, LOC Bank of New York, New York, CP](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [57599LDJ6](#)

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-10](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-10](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF NEW YORK MELLON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$15,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$15,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.29%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$15,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$15,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Port Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Port Auth. Rev., 0.18% Series 2003 B, LOC Bank of New York, New York, CP](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [57599LDQ0](#)

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
 Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
 Brief description: (optional): [Not Provided]
 Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
 Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
 Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-17](#)
 Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-17](#)
 Item 37. Does the security have a Demand Feature? [No](#)
 Item 38. Does the security have a Guarantee? [Yes](#)

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF NEW YORK MELLON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
 Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$15,000,000.00](#)
 Item 41. The total current amortized cost, to the nearest cent: [\\$15,000,000.00](#)
 Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.29%](#)
 Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
 Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
 Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$15,000,000.00](#)
 Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$15,000,000.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Port Auth. Rev.](#)
 Item 27. The title of the issue (including coupon or yield): [Massachusetts Port Auth. Rev., 0.18% Series 2003 B, LOC Bank of New York, New York, CP](#)
 Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]
 Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [57599LDM9](#)
 Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
 Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
 Brief description: (optional): [Not Provided]
 Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
 Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)
 Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-18](#)
 Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-18](#)

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF NEW YORK MELLON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$15,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$15,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.29%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$15,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$15,000,000.00**

Security

Item 26. The name of the issuer: **Massachusetts Port Auth. Rev.**

Item 27. The title of the issue (including coupon or yield): **Massachusetts Port Auth. Rev., 0.18% Series 2003 B, LOC Bank of New York, New York, CP**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **57599LDL1**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Municipal Debt**
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2012-01-19**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2012-01-19**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF NEW YORK MELLON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$14,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$14,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.27%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$14,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$14,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Port Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Port Auth. Rev., 0.18% Series 2003 B, LOC Bank of New York, New York, CP](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [57599LDN7](#)

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-01-23](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-01-23](#)

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
BANK OF NEW YORK MELLON	N/A	N/A

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$10,000,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$10,000,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.19%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$10,000,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$10,000,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Port Auth. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Port Auth. Rev., 3.00% Bonds Series 2010 C](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [575896HQ1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-07-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-07-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$500,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$507,922.08](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.01%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$508,170.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$508,170.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Spl. Oblig. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Spl. Oblig. Rev., 1.00% Bonds \(Sr. Fed. Hwy. Grant Anticipation Note Prog.\) Series 2010 A](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [576004GE9](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-15](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-15](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	MASSACHUSETTS ST FED HWY	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$32,500,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$32,525,756.02](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.63%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$32,532,500.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$32,532,500.00](#)

Security

Item 26. The name of the issuer: [Massachusetts State Dev. Fin. Agcy. Elec. Util. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts State Dev. Fin. Agcy. Elec. Util. Rev., 0.60% Bonds \(Nantucket Elec. Co. Proj.\) Series 2007 tender 11/02/2011, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57584TAA8](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Second Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-02](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-02](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [Yes](#)

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	NANTUCKET ELEC CO	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$12,200,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$12,200,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.24%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$12,200,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$12,200,000.00**

Security

Item 26. The name of the issuer: [Massachusetts State Dev. Fing. Agcy. Poll. Cont. Rev.](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts State Dev. Fing. Agcy. Poll. Cont. Rev., 0.90% Bonds \(Massachusetts Elec. Co. Proj.\) Series 2004 M, tender 11/02/2011, CP Mode](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57584LAB3](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Second Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-02](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-02](#)

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **Yes**

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	MASS ELECTRIC CO	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$200,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$200,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.00%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$200,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$200,000.00**

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Poll. Abatement Trust](#)

Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Poll. Abatement Trust, 5.00% Bonds Series 2002 A, \(Pre-Refunded to 8/1/2012 @ 100\)](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57604PL69](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]
Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)
Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-08-01](#)
Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-08-01](#)
Item 37. Does the security have a Demand Feature? [No](#)
Item 38. Does the security have a Guarantee? [No](#)
Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$1,000,000.00](#)
Item 41. The total current amortized cost, to the nearest cent: [\\$1,035,741.39](#)
Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.02%](#)
Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
Item 44. Is this an Illiquid Security as of the date of this report? [No](#)
Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$1,035,530.00](#)
Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$1,035,530.00](#)

Security

Item 26. The name of the issuer: [Massachusetts Wtr. Poll. Abatement Trust](#)
Item 27. The title of the issue (including coupon or yield): [Massachusetts Wtr. Poll. Abatement Trust, 5.00% Bonds Series 14](#)
Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [57604PV50](#)
Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]
Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)
Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)
Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-08-01](#)
Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-08-01](#)
Item 37. Does the security have a Demand Feature? [No](#)
Item 38. Does the security have a Guarantee? [No](#)
Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)
Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$7,800,000.00](#)

- Item 41. The total current amortized cost, to the nearest cent: **\$8,077,645.18**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.16%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$8,074,794.00**
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$8,074,794.00**

Security

- Item 26. The name of the issuer: **Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev.**
- Item 27. The title of the issue (including coupon or yield): **Massachusetts Wtr. Resources Auth. Wtr. & Swr. Rev., 0.16% Series 99, LOC State Street Bank & Trust Co., Boston, CP**
- Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [Not Provided]
- Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **5760519S7**
- Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]
- Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Municipal Debt**
Brief description: (optional): [Not Provided]
- Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**
- Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**
- Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

- Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-10**
- Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-10**
- Item 37. Does the security have a Demand Feature? **No**
- Item 38. Does the security have a Guarantee? **Yes**

Guarantor	Designated NRSRO(s) for the Guarantee or Guarantor	Credit rating of the Guarantor
STATE ST BK & TR CO BOSTON	N/A	N/A

- Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**
- Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$18,000,000.00**
- Item 41. The total current amortized cost, to the nearest cent: **\$18,000,000.00**
- Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.35%**
- Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:
- Item 44. Is this an Illiquid Security as of the date of this report? **No**
- Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$18,000,000.00**
- Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$18,000,000.00**

Security

- Item 26. The name of the issuer: **Melrose Gen. Oblig.**

Item 27. The title of the issue (including coupon or yield): [Melrose Gen. Oblig., 0.90% BAN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [585565PB4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-17](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-17](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$5,270,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$5,271,488.33](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.10%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$5,271,686.40](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$5,271,686.40](#)

Security

Item 26. The name of the issuer: [Melrose Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Melrose Gen. Oblig., 1.50% BAN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [585565PA6](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)

Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-17](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-17](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,725,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,726,139.57](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.05%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,726,526.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,726,526.00](#)

Security

Item 26. The name of the issuer: [Middleton Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Middleton Gen. Oblig., 1.50% BAN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [596731ES4](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-12-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-12-07](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$15,850,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$15,867,275.19](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.31%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$15,872,031.50](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$15,872,031.50](#)

Security

Item 26. The name of the issuer: [Nantucket Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Nantucket Gen. Oblig., 1.50% BAN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [630191TT1](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-02-24](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-02-24](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$5,750,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$5,769,696.81](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.11%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$5,772,712.50](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$5,772,712.50](#)

Security

Item 26. The name of the issuer: [Needham Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Needham Gen. Oblig., 1.50% BAN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [639846E91](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-06-15](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-06-15](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$5,762,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$5,807,271.92**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.11%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$5,807,462.18**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$5,807,462.18**

Security

Item 26. The name of the issuer: **Shrewsbury Gen. Oblig.**

Item 27. The title of the issue (including coupon or yield): **Shrewsbury Gen. Oblig., 1.50% BAN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **825502WH6**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Municipal Debt**
Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2012-07-13**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2012-07-13**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$3,625,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$3,654,178.76**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.07%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$3,654,326.25**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$3,654,326.25**

Security

Item 26. The name of the issuer: **Stow Gen. Oblig.**

Item 27. The title of the issue (including coupon or yield): **Stow Gen. Oblig., 1.50% BAN**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [862378GV2](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [First Tier Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-09-28](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-09-28](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$6,700,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$6,773,881.86](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.13%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$6,773,432.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$6,773,432.00](#)

Security

Item 26. The name of the issuer: [Tewksbury Gen. Oblig.](#)

Item 27. The title of the issue (including coupon or yield): [Tewksbury Gen. Oblig., 1.00% BAN](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [881626B87](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-02-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-02-07](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **No**

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$10,350,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$10,364,224.21**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.20%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$10,363,765.50**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$10,363,765.50**

Security

Item 26. The name of the issuer: **Univ. of Massachusetts Bldg. Auth. Facilities Rev.**

Item 27. The title of the issue (including coupon or yield): **Univ. of Massachusetts Bldg. Auth. Facilities Rev., 2.50% Bonds Series 2010-1**

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: **914440KN1**

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: **[Not Provided]**

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: **Other Municipal Debt**
Brief description: (optional): **[Not Provided]**

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? **No**

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: **First Tier Security**

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): **2011-11-01**

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: **2011-11-01**

Item 37. Does the security have a Demand Feature? **No**

Item 38. Does the security have a Guarantee? **No**

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? **Yes**

Type of enhancement	Enhancement provider	Designated NRSRO(s) for the enhancement or the enhancement provider	Credit rating of the enhancement provider
OBLIGOR	UNIV OF MASSACHUSETTS	N/A	N/A

Item 40. The total principal amount of the security held by the series, to the nearest cent: **\$4,710,000.00**

Item 41. The total current amortized cost, to the nearest cent: **\$4,710,000.00**

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: **0.09%**

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? **No**

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: **\$4,710,000.00**

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: **\$4,710,000.00**

Security

Item 26. The name of the issuer: [Wayland Massachusetts](#)

Item 27. The title of the issue (including coupon or yield): [Wayland Massachusetts, 2.00% Bonds](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [944216XE5](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Other Municipal Debt](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2012-02-01](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2012-02-01](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$2,430,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$2,439,576.66](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [0.05%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$2,440,910.70](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$2,440,910.70](#)

Security

Item 26. The name of the issuer: [Fidelity Revere Str Trust](#)

Item 27. The title of the issue (including coupon or yield): [Fidelity Municipal Cash Central Fund, 0.10%](#)

Item 28. The CUSIP. If the security has a CUSIP, filers must provide the security's CUSIP pursuant to this Item and may skip Items 29 and 30: [31635A204](#)

Item 29. Other unique identifier, if the security has a unique identifier. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 30. CIK of the issuer, if the issuer has a CIK. If a CUSIP is provided pursuant to Item 28, skip this Item: [Not Provided]

Item 31. The category of investment. Indicate the category that most closely identifies the instrument: [Investment Company](#)
Brief description: (optional): [Not Provided]

Item 32. If the security is a Repurchase agreement: is fund treating the acquisition of the repurchase agreement as the acquisition of the underlying securities (i.e. collateral) for the purposes of portfolio diversification under rule 2a-7? [No](#)

Item 33. Rating. Indicate whether the security is a rated First Tier Security, rated Second Tier Security, an Unrated Security, or no longer an Eligible Security: [Unrated Security](#)

Item 34. Name of each Designated NRSRO:

Name of Designated NRSRO	Credit rating given by the Designated NRSRO
--------------------------	---

Item 35. The maturity date as determined under rule 2a-7. Determine the maturity date, taking into account the maturity shortening provisions of rule 2a-7(d): [2011-11-07](#)

Item 36. The final legal maturity date, taking into account any maturity date extensions that may be effected at the option of the issuer: [2011-11-07](#)

Item 37. Does the security have a Demand Feature? [No](#)

Item 38. Does the security have a Guarantee? [No](#)

Item 39. Does the security have any enhancements, other than those identified in Items 37 and 38 above, on which the fund is relying to determine the quality, maturity or liquidity of the security? [No](#)

Item 40. The total principal amount of the security held by the series, to the nearest cent: [\\$733,042,000.00](#)

Item 41. The total current amortized cost, to the nearest cent: [\\$733,042,000.00](#)

Item 42. The percentage of the money market fund's net assets invested in the security, to the nearest hundredth of a percent: [14.22%](#)

Item 43. Explanatory notes. Disclose any other information that may be material to other disclosures related to the portfolio security:

Item 44. Is this an Illiquid Security as of the date of this report? [No](#)

Item 45. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), including the value of any capital support agreement: [\\$733,042,000.00](#)

Item 46. The value of the security, calculated using available market quotations (or an appropriate substitute that reflects current market conditions), excluding the value of any capital support agreement: [\\$733,042,000.00](#)